Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.
Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G.
Bröker LE, et al. Among authors: de vries eg, de vos fy.
Clin Cancer Res. 2006 Mar 15;12(6):1760-7. doi: 10.1158/1078-0432.CCR-05-2093.
Clin Cancer Res. 2006.
PMID: 16551860
Free article.
Clinical Trial.